SHANDONG JINCHENG PHARMACEUTICAL GROUP CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.51 CNY | +1.85% |
|
+8.62% | -0.90% |
| Sales 2022 | 3.51B 484M 661M | Sales 2023 | 3.54B 488M 668M | Capitalization | 6.34B 874M 1.2B |
|---|---|---|---|---|---|
| Net income 2022 | 273M 37.68M 51.51M | Net income 2023 | 175M 24.15M 33.02M | EV / Sales 2022 | 2.43 x |
| Net cash position 2022 | 208M 28.74M 39.29M | Net cash position 2023 | 471M 64.94M 88.78M | EV / Sales 2023 | 1.66 x |
| P/E ratio 2022 |
32.1
x | P/E ratio 2023 |
37
x | Employees | 3,806 |
| Yield 2022 |
0.66% | Yield 2023 |
1.2% | Free-Float | 29.66% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.85% | ||
| 1 week | +8.62% | ||
| Current month | +7.28% | ||
| 1 month | +4.23% | ||
| 3 months | +15.21% | ||
| 6 months | -6.46% | ||
| Current year | -0.90% |
1 week
15.21
16.54
1 month
14.8116.74
Current year
10.8317.05
1 year
10.8322.09
3 years
10.8344.98
5 years
10.8344.98
10 years
9.9659.83
| Managers | Title | Age | Since |
|---|---|---|---|
Jia Quan Li
PSD | President | 52 | 08-01-31 |
Jing Liu
DFI | Director of Finance/CFO | 48 | - |
Geng Xiu Zheng
CTO | Chief Tech/Sci/R&D Officer | 60 | 03-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ye Qing Zhao
CHM | Chairman | 47 | 04-06-30 |
Jia Quan Li
PSD | President | 52 | 08-01-31 |
Xi Li Cui
BRD | Director/Board Member | 51 | 08-02-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 16.51 | +1.85% | 5,568,190 |
| 24-04-25 | 16.21 | +3.78% | 6,766,101 |
| 24-04-24 | 15.62 | +1.03% | 3,144,800 |
| 24-04-23 | 15.46 | +1.18% | 3,776,105 |
| 24-04-22 | 15.28 | +0.53% | 3,515,601 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Shandong Jincheng Pharmaceutical Group Co., Ltd., formerly Shandong Jincheng Pharmaceutical Co., Ltd., is a China-based company principally engaged in the research, development, production and sale of cephems medicine intermediates. The Company mainly provides active ester side chain of cephalosporin products, other pharmaceutical chemical products, as well as bio-pharmaceuticals and specialty active pharmaceutical ingredient (API). The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.90% | 875M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 300233 Stock
